COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0
|
作者：
Petropoulos, A. [1 ]
Cooney, P. [2 ]
Patidar, M. [3 ]
Gudala, K. [3 ]
Tiwari, S. [4 ]
Brennan, R. [2 ]
Kapsogeorgiou, K. [1 ]
Cheilas, G. [1 ]
Banhazi, J. [5 ]
机构：
[1] Novartis Hellas SACI, Athens A1, Greece
[2] Novartis Ireland Ltd, Dublin, Ireland
[3] Novartis Healthcare Private Ltd, Hyderabad, India
[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India
[5] Novartis Pharma AG, Basel, BS, Switzerland
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE143
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [21] Cost-Effectiveness of Disease-Modifying Therapies for the Treatment of Patients with Highly Active Multiple Sclerosis - Swedish Perspective
    O'Day, Ken
    Deniz, Baris
    Meyer, Kellie
    NEUROLOGY, 2012, 78
  • [22] Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
    Iannazzo, Sergio
    Iliza, Ange-Christelle
    Perrault, Louise
    PHARMACOECONOMICS, 2018, 36 (02) : 189 - 204
  • [23] Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
    Sergio Iannazzo
    Ange-Christelle Iliza
    Louise Perrault
    PharmacoEconomics, 2018, 36 : 189 - 204
  • [24] Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis
    Parekh, Krupa
    Watkins, Claire
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (17) : 1265 - 1266
  • [25] COST-CONSEQUENCE ANALYSIS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE-MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA
    Farhane, F.
    Bhan, V
    Clift, F.
    Baharnoori, M.
    Thomas, K.
    Patel, B. P.
    Blanchette, F.
    Adlard, N. E.
    Vudumula, U.
    Gudala, K.
    Dutta, N.
    Grima, D.
    Mouallif, S.
    VALUE IN HEALTH, 2022, 25 (12) : S55 - S56
  • [26] Effectiveness and Cost-Effectiveness of 360 Disease-Modifying Treatment Escalation Sequences in Multiple Sclerosis
    Versteegh, Matthijs M.
    Huygens, Simone A.
    Wokke, Beatrijs W. H.
    Smolders, Joost
    VALUE IN HEALTH, 2022, 25 (06) : 984 - 991
  • [27] Cost of disease-modifying therapies for multiple sclerosis
    Brown, Murray G.
    NEUROLOGY, 2015, 84 (21) : E181 - E185
  • [28] COST-EFFECTIVENESS ANALYSIS OF OFATUMUMAB FOR RELAPSING REMITTING MULTIPLE SCLEROSIS TREATMENT IN ITALY
    Antonazzo, I. C.
    Nica, M.
    Cortesi, P.
    Ritrovato, D.
    Mantovani, L. G.
    VALUE IN HEALTH, 2022, 25 (12) : S342 - S343
  • [29] Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis
    Goldberg, Lawrence D.
    Edwards, Natalie C.
    Fincher, Contessa
    Doan, Quan V.
    Al-Sabbagh, Ahmad
    Meletiche, Dennis M.
    JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (07): : 543 - 555
  • [30] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
12345